Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been assigned an average rating of “Hold” from the fourteen research firms that are covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $17.56.

Several research firms have issued reports on IRWD. Credit Suisse Group began coverage on Ironwood Pharmaceuticals in a research note on Monday, November 27th. They set a “buy” rating and a $19.00 target price for the company. ValuEngine cut Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Mizuho cut Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $20.00 to $16.00 in a research note on Wednesday, December 6th. BidaskClub cut Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Zacks Investment Research cut Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th.

In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 113,405 shares of the firm’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the completion of the sale, the chief executive officer now owns 4,696,917 shares of the company’s stock, valued at $71,017,385.04. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 115,769 shares of company stock valued at $1,752,491. 7.63% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Sawyer & Company Inc acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at $615,000. Public Employees Retirement System of Ohio grew its stake in shares of Ironwood Pharmaceuticals by 4.8% in the third quarter. Public Employees Retirement System of Ohio now owns 120,888 shares of the biotechnology company’s stock valued at $1,906,000 after buying an additional 5,513 shares in the last quarter. California Public Employees Retirement System grew its stake in shares of Ironwood Pharmaceuticals by 7.1% in the third quarter. California Public Employees Retirement System now owns 246,617 shares of the biotechnology company’s stock valued at $3,889,000 after buying an additional 16,417 shares in the last quarter. Granahan Investment Management Inc. MA grew its stake in shares of Ironwood Pharmaceuticals by 24.5% in the third quarter. Granahan Investment Management Inc. MA now owns 436,000 shares of the biotechnology company’s stock valued at $6,876,000 after buying an additional 85,904 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its stake in shares of Ironwood Pharmaceuticals by 30.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 23,405 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 5,527 shares in the last quarter.

Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at $15.12 on Monday. Ironwood Pharmaceuticals has a 1 year low of $13.43 and a 1 year high of $19.94. The company has a market capitalization of $2,264.30, a P/E ratio of -15.59 and a beta of 1.45. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The firm had revenue of $86.80 million for the quarter, compared to the consensus estimate of $73.59 million. During the same quarter last year, the business posted ($0.18) earnings per share. The firm’s revenue was up 31.3% compared to the same quarter last year. analysts forecast that Ironwood Pharmaceuticals will post -1.12 EPS for the current year.

WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/15/ironwood-pharmaceuticals-inc-irwd-given-consensus-recommendation-of-hold-by-brokerages.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.